Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. Clementia is preparing to submit an NDA in the second half of 2019 to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of investigational palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of MO, also known as multiple hereditary exostoses (MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
Company profile
Ticker
CMTA
Exchange
Website
CEO
Clarissa Desjardins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
29 Apr 19
EFFECT
Notice of effectiveness
19 Apr 19
25-NSE
Exchange delisting
18 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Apr 19
POS AM
Prospectus update (post-effective amendment)
18 Apr 19
6-K
Ipsen Completes Acquisition of
18 Apr 19
6-K
Current report (foreign)
11 Apr 19
6-K
Current report (foreign)
9 Apr 19
20-F
2018 FY
Annual report (foreign)
29 Mar 19
6-K
Report of Foreign Private Issuer for the Month of March 2019
13 Mar 19
Latest ownership filings
SC 13D
Clementia Pharmaceuticals Inc.
13 Mar 19
SC 13D
Clementia Pharmaceuticals Inc.
6 Mar 19
SC 13D/A
Clementia Pharmaceuticals Inc.
1 Mar 19
SC 13G
Clementia Pharmaceuticals Inc.
13 Feb 19
SC 13G/A
Clementia Pharmaceuticals Inc.
13 Feb 19
SC 13G
Clementia Pharmaceuticals Inc.
12 Feb 19
SC 13G/A
Clementia Pharmaceuticals Inc.
12 Feb 19
SC 13D/A
Clementia Pharmaceuticals Inc.
5 Nov 18
SC 13G
Clementia Pharmaceuticals Inc.
14 Feb 18
SC 13G
Clementia Pharmaceuticals Inc.
8 Feb 18
Institutional ownership, Q4 2019
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Proequities | 0.00 | $0.00 |